SYNAPSECATALYSTADVISORY

Innovation Diagnostic
A structured diagnostic for Pharma, MedTech, and Healthcare enterprise leaders.

Complete the diagnostic candidly. It identifies the execution gaps, cultural friction points, and strategic misalignments that constrain innovation velocity in regulated environments.

Step 1 of 11
Score: 0 / 110 · Category: Not yet calculated
9% complete

How this diagnostic works

25 minutes. The most valuable diagnostic your innovation function will run this quarter.

This instrument evaluates your organization’s innovation capability across six evidence-based pillars derived from peer-reviewed doctoral research on healthcare entrepreneurial leadership.

Rating scale
1 — Not at All / Very Low · 2 — Low / Early Stage · 3 — Moderate / Developing · 4 — High / Consistent · 5 — Excellent / Systematized

PROFILE

Help us interpret your diagnostic by organization profile

These fields improve segmentation, comparison across cohorts, and consultation prep.

0.
What is the name of your organization?
Use the legal or operating name you want associated with the report.
Pillar 1

Innovation Management

Processes, Systems & Execution Velocity

This pillar assesses whether your organization has engineered the repeatable systems, stage-gate disciplines, and idea-to-impact infrastructure required to move from ideation to R&D or commercial adoption — at speed.

1.
How structured and flexible is your end-to-end process for capturing, evaluating, advancing, and learning from innovation initiatives — including intelligent failure?
Consider: Do you have a defined idea-to-impact pipeline? Are stage-gate decisions evidence-driven? Is failure systematically captured and redirected?
2.
To what extent does your organization allocate dedicated, protected resources specifically for innovation activity?
Consider: Is innovation resourced on a sustained basis, or episodically funded through project surpluses?
3.
How effectively do your innovation processes navigate regulatory complexity while preserving speed-to-market and operational agility?
Consider: GCP alignment, regulatory pathway integration, risk-stratified experimentation protocols.
4.
What percentage of your active innovation portfolio is genuinely breakthrough or transformational versus incremental optimization of existing products or services?
A portfolio weighted above 85% toward incremental activity is a leading indicator of strategic drift and declining competitive positioning.

Consulting insight: where gaps in this pillar show up

Organizations scoring below 3.0 in Innovation Management demonstrate two high-cost failure modes: perpetual ideation without disciplined implementation, and governance structures so rigid they strangle entrepreneurial velocity. Both are solvable through architectural redesign — not cultural mandates. We’ll discuss this pillar specifically in your complimentary 30-minute consultation.

Pillar 2

Innovation Strategy

Portfolio Architecture, Strategic Alignment & Risk Calibration

Innovation without strategy is expensive experimentation. This pillar evaluates whether your innovation portfolio is architected for competitive differentiation — not just activity — and whether your capital allocation reflects deliberate horizon management across core, adjacent, and transformational initiatives.

5.
How clearly is your innovation investment linked to overarching corporate strategy, competitive positioning, and measurable business objectives?
Consider: Can every active initiative be mapped to a strategic priority? Is there a clear line of sight from innovation output to enterprise value creation?
6.
How effectively does your organization balance the innovation portfolio across core optimization, adjacent market expansion, and transformational bets — with calibrated risk management at each horizon?
Research benchmark: High-performing healthcare organizations maintain a 70/20/10 portfolio allocation. Portfolios weighted above 85% toward core are managing entropy, not driving growth.
7.
How effectively do senior leaders communicate innovation priorities, align cross-functional stakeholders, and sustain strategic commitment across business cycles?
Consider: Are innovation priorities stable across leadership transitions? Is there executive-level sponsorship for Horizon 2/3 initiatives?
8.
To what degree do quarterly or annual strategy reviews incorporate innovation performance data, competitive landscape analysis, and course-correction mechanisms?
Consider: Is innovation a standing agenda item with defined metrics, or reviewed episodically?

Consulting insight: the cost of portfolio imbalance

Organizations allocating more than 90% of innovation capital to Horizon 1 initiatives demonstrate stagnating pipelines within 24–36 months. The strategic math is unforgiving — incremental optimization cannot outpace disruptive market entrants. We’ll discuss this pillar specifically in your complimentary 30-minute consultation.

Pillar 3

Innovation Performance

Metrics Architecture, Accountability & Value Realization

Effective innovation performance management requires a measurement architecture that evolves with the maturity of each initiative — from learning velocity metrics in early-stage exploration to ROI and R&D adoption rates at scale.

9.
How well-defined, consistently tracked, and strategically actionable are your innovation-specific KPIs — spanning input indicators, process velocity, output measures, and outcome realization beyond standard financial metrics?
Consider: Do your metrics distinguish between discovery-stage learning velocity and scale-stage commercial adoption? Are innovation KPIs reviewed with the same rigor as operational KPIs?
10.
To what extent are teams held accountable for innovation outcomes within a psychologically safe environment that distinguishes intelligent failure from avoidable failure?
Consider: Does your accountability framework incentivize bold experimentation, or create defensive conservatism that suppresses entrepreneurial risk-taking?
11.
In your regulatory environment, how do you measure and communicate the ROI, adoption velocity, and stakeholder value realization of innovation initiatives — particularly those with multi-year development timelines?
Open Response: Describe your current measurement and reporting approach.
12.
How do you personally track, review, and communicate innovation performance upward to the board and laterally across functional stakeholders?
Open Response: Describe your current leadership reporting practice.

Consulting insight: the measurement trap

The most common innovation performance failure mode in enterprise healthcare: applying Horizon 1 financial metrics to Horizon 3 initiatives. Demanding IRR projections from a $25K discovery pilot doesn’t eliminate risk — it eliminates velocity. We’ll discuss this pillar specifically in your complimentary 30-minute consultation.

Pillar 4

Innovation Leadership

Entrepreneurial Leadership Proficiencies & Talent Architecture

This pillar evaluates the most decisive variable in innovation performance: the caliber of entrepreneurial leadership at every level of the organization. Leadership proficiency — not capital allocation alone — is the primary differentiator between organizations that sustain innovation velocity and those that stall at the pilot stage.

13.
How comfortable are senior leaders and innovation sponsors with calculated risk-taking, operational ambiguity, and iterative experimentation in regulated environments — without defaulting to analysis paralysis or compliance conservatism?
Consider: Can leaders make high-quality decisions with 70% information? Do they model risk-taking behavior that enables frontline entrepreneurial action?
14.
To what extent do leaders at all levels demonstrate entrepreneurial behaviors — including opportunity recognition, cross-functional collaboration, creative problem-solving, and proactive stakeholder engagement?
Consider: Is entrepreneurial leadership modeled from the C-suite, or confined to a dedicated innovation function with limited organizational influence?
15.
How effectively does senior leadership empower cross-functional teams, cultivate cognitive diversity, and foster the Innovative Work Behaviors — idea generation, championing, and realization — necessary for sustained innovation performance?
Consider: Is empowerment structural (clear decision rights, protected time, metered funding) or merely rhetorical?
16.
To what extent does your organization invest in structured talent development programs that cultivate entrepreneurial mindsets, skills, and behaviors — including mentoring, coaching, capability building, and leadership acceleration pathways?
Consider: Hiring innovative talent is insufficient without systematic development architecture to scale entrepreneurial capacity across the enterprise.
17.
On a scale of 1–5, how would you rate your own entrepreneurial leadership capability in catalyzing innovation performance within your current organizational context?
Consider your proficiency across: strategic foresight, ambiguity tolerance, psychological capital, radical empathy, and pivot discipline.

Consulting insight: the leadership capacity gap

The most consistent finding in our research: organizations that plateau at the pilot stage have a leadership capacity gap — not a capital gap or an idea gap. Without a systematized approach to scaling entrepreneurial proficiencies across the organization, innovation velocity remains dependent on heroic individuals rather than durable institutional capability. We’ll discuss this pillar specifically in your complimentary 30-minute consultation.

Pillar 5

Innovation & Change

Adoption Velocity, Stakeholder Conversion & Cultural Transformation

Innovation that cannot be adopted is not innovation — it is expensive experimentation. This pillar evaluates your organization’s structured ability to convert stakeholder resistance into co-sponsorship, accelerate R&D and operational adoption of novel solutions, and embed an entrepreneurial orientation as a durable cultural norm.

18.
How effective are your change management processes when scaling innovation initiatives — including stakeholder alignment, communication architecture, sponsor network development, and adoption velocity tracking?
Consider: Do you apply a structured change management methodology systematically to innovation rollouts, or is change management handled ad hoc?
19.
What is the typical level of organizational resistance encountered when introducing innovation at scale, and how effectively is that resistance converted into active co-sponsorship?
Reverse-score for analysis. High resistance with low conversion capability is a leading indicator of innovation fatigue.
20.
How proficient are senior leaders in guiding stakeholders through uncertainty and organizational transformation — particularly in regulated environments where compliance anxiety amplifies change resistance?
Consider: Do leaders have a structured toolkit for translating innovation risk into stakeholder-specific value narratives?
21.
To what extent is an entrepreneurial and innovative mindset embedded in the organizational operating model — versus treated as a separate function or periodic initiative disconnected from core business operations?
Consider: Is ‘innovation’ a department, or a distributed organizational capability?

Consulting insight: innovation fatigue

One of the most consequential — and least discussed — dynamics in enterprise healthcare is innovation fatigue: the compounding organizational exhaustion from repeated cycles of promising pilots that fail to achieve sustained adoption. Each failed rollout reduces stakeholder confidence, executive sponsorship appetite, and frontline engagement. We’ll discuss this pillar specifically in your complimentary 30-minute consultation.

Pillar 6

Innovation Orientation

Entrepreneurial Mindset, Ecosystem Strategy & Long-Term Value Architecture

Innovation orientation captures the deepest layer of organizational competitive advantage: the collective entrepreneurial mindset and long-horizon strategic posture that transforms reactive organizations into proactive market architects.

22.
How strong and pervasive is a long-term, learning-oriented, and ecosystem-integrated mindset across the organization — from frontline R&D teams to executive leadership?
Consider: Is continuous learning infrastructure embedded in how innovation work is conducted — or reserved for formal training events?
23.
To what extent does leadership systematically consider the full value lifecycle of innovations — including sustainability, health equity, patient outcomes, and broader societal impact — as integral to strategic decision-making?
Consider: Is long-term value architecture part of your innovation governance criteria, or primarily a compliance and ESG reporting exercise?
24.
How open, systematic, and strategically disciplined is your organization’s approach to external partnerships, open innovation platforms, academic alliances, venture ecosystems, and disruptive talent networks?
Consider: Is external innovation a reactive tactic or a proactive capability?
25.
How would you characterize your personal leadership orientation: future-focused, adaptive, and entrepreneurially committed — versus primarily operationally focused, risk-mitigating, and stability-oriented?
This item surfaces the leadership identity dimension of entrepreneurial orientation.

Consulting insight: orientation as competitive moat

An entrepreneurial orientation is not a personality trait — it is a learnable, measurable capability. We’ll discuss this pillar specifically in your complimentary 30-minute consultation.

Reflection

Two priority prompts to close the diagnostic

These responses form the foundation of your executive debrief and strategic roadmap.

26.
What is your single most consequential innovation challenge right now — the barrier that, if removed, would have the highest multiplier effect on your organization’s innovation performance trajectory?
Consider: Is it a leadership capability gap? A governance architecture constraint? A cultural friction point? A portfolio misalignment? A change adoption deficit?
27.
On a scale of 1–10, how urgent is it to materially strengthen your organization’s innovation engine within the next 12 months — given your current competitive environment, pipeline pressures, and market dynamics?
1–3: adequate. 4–6: growing pressure. 7–10: immediate action required.

Personalize your report

Enter your details to unlock your results

Your personalized Innovation Diagnostic Report is ready. Enter your details below to receive your results and claim your complimentary 30-minute consultation.

We’ll use this to send your report and schedule your complimentary 30-minute consultation.
Your next move

From diagnosis to competitive advantage

Your diagnostic has generated an evidence-based snapshot of your innovation enablement posture. The next step is a selective, value-focused review.

Innovation Diagnostic Score Summary

Innovation Pillar Q Items Max Score Your Score Gap
1. Innovation ManagementQ1–Q3150 / 1515
2. Innovation StrategyQ5–Q8200 / 2020
3. Innovation PerformanceQ9–Q10100 / 1010
4. Innovation LeadershipQ13–Q17250 / 2525
5. Innovation & ChangeQ18–Q21200 / 2020
6. Innovation OrientationQ22–Q25200 / 2020
TOTAL ENABLEMENT SCOREQ1–Q251100 / 110110
Score band Performance category Best-fit services Company benefit
22–44 Critical Friction Innovation Gap Analysis, executive debrief, architecture reset roadmap, leadership alignment session Stops leakage fast, identifies the real bottlenecks, and creates a prioritized recovery plan before erosion deepens.
45–66 Developing Capability Targeted workshop, leader coaching, pillar-specific diagnostics, operating model tuning Converts scattered effort into repeatable execution, reduces cultural drag, and improves adoption and decision quality.
67–88 Advancing Performance Strategy call, portfolio rebalance engagement, change orchestration design, performance metrics redesign Accelerates velocity, improves portfolio mix, and scales what is already working without wasting momentum.
89–110 Innovation-Enabled Renewal & scalability assessment, succession planning, ecosystem strategy, executive coaching for sustainment Protects the moat, institutionalizes innovation, and reduces dependence on heroic individuals.

Thank you

To receive a personalized interpretation of your results, send them directly to Dr. Jason D’Souza at jasondsouza@synapsecatalystadvisory.com. No obligation — just a more informed starting point. Book your complimentary 30-minute consultation directly: